ANI PHARMACEUTICALS INC (ANIP) Stock Price, Forecast & Analysis
NASDAQ:ANIP • US00182C1036
ANIP Key Statistics, Chart & Performance
The current stock price of ANIP is 73.9 USD. In the past month the price decreased by -9.88%. In the past year, price increased by 19.41%.
ANIP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP turns out to be only a medium performer in the overall market: it outperformed 49.01% of all stocks.
ANIP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ANIP. ANIP has only an average score on both its financial health and profitability.
ANIP Financial Highlights
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 7.17. The EPS increased by 56.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.13% | ||
| ROA | 2.42% | ||
| ROE | 6.75% | ||
| Debt/Equity | 1.2 |
ANIP Forecast & Estimates
14 analysts have analysed ANIP and the average price target is 111.91 USD. This implies a price increase of 51.43% is expected in the next year compared to the current price of 73.9.
For the next year, analysts expect an EPS growth of 48.17% and a revenue growth 44.85% for ANIP
ANIP Ownership
ANIP Latest News, Press Relases and Analysis
ANIP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANIP
Company Profile
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Company Info
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 897
Phone: 13026587581
ANI PHARMACEUTICALS INC / ANIP FAQ
What does ANIP do?
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Can you provide the latest stock price for ANI PHARMACEUTICALS INC?
The current stock price of ANIP is 73.9 USD. The price decreased by -4.21% in the last trading session.
What is the dividend status of ANI PHARMACEUTICALS INC?
ANIP does not pay a dividend.
How is the ChartMill rating for ANI PHARMACEUTICALS INC?
ANIP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is ANI PHARMACEUTICALS INC (ANIP) stock traded?
ANIP stock is listed on the Nasdaq exchange.
What is ANI PHARMACEUTICALS INC worth?
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.66B USD. This makes ANIP a Small Cap stock.
Can you provide the ownership details for ANIP stock?
You can find the ownership structure of ANI PHARMACEUTICALS INC (ANIP) on the Ownership tab.